Hepatocellular Cancer Surveillance in Patients with Advanced Chronic Liver Disease

Our algorithm stratified patients into two groups: those at higher risk of developing HCC and those at lower risk. Our data provide equipoise to test the prospective utility of the algorithm with respect to clinical decisions about screening patients with ACLD for incident HCC. (Funded by the German Research Foundation and others; ClinicalTrials.gov number, NCT03389152.).

Authors

Institutions

Publication Details

Journal
NEJM Evidence
Published
2024-10-22
DOI
https://doi.org/10.1056/evidoa2400062
Citations
11
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
4.25
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Hepatocellular Cancer Surveillance in Patients with Advanced Chronic Liver Disease

Ali Canbay, Valérie Vilgrain, David Bauer, Laurent Castéra et al.
11 citations
NEJM Evidence
Liver Disease Diagnosis and Treatment
4.25
article

Hepatocellular Cancer Surveillance in Patients with Advanced Chronic Liver Disease

Ali Canbay, Valérie Vilgrain, David Bauer, Laurent Castéra, Cristina Margini, Maximilian Joseph Brol, Benedikt Simbrunner, Jonel Trebicka, Robert Schierwagen, Philipp Schindler, Aleksander Krag, Ivica Grgurević, Ioan Sporea, Adèle Delamarre, Camille Vassord, Halima Gottfriedová, Victor de Lédinghen, Ditlev Nytoft Rasmussen, Annalisa Berzigotti, Mireen Friedrich‐Rust, Frank Erhard Uschner, Michael Praktiknjo, Martin Schulz, Wim Laleman, Sabine Klein, Maja Thiele, Aymeric Guibal, Yasmin Zeleke, Jérôme Boursier, Georg Semmler, Renáta Šenkeříková, Julia Fischer, Sven Francque, Jan Best, Florian Rennebaum, Thomas Reiberger, Christian Peer Strassburg, Luisa Vonghia, Jérôme Dumortier, Wen‐Ping Wang, Christian Jansen, Christophe Aubé, S. Pol, S Zeuzem, Alina Popescu, Wenyi Gu
article en
11 citations

Abstract

Our algorithm stratified patients into two groups: those at higher risk of developing HCC and those at lower risk. Our data provide equipoise to test the prospective utility of the algorithm with respect to clinical decisions about screening patients with ACLD for incident HCC. (Funded by the German Research Foundation and others; ClinicalTrials.gov number, NCT03389152.).

NEJM EvidenceVol. 3(11)
Goethe University Frankfurt (DE), University of Bern (CH), Université de Bordeaux (FR), Inserm (FR), Institut Pasteur (FR), University of Zagreb (HR), Université Paris Cité (FR), University of Münster (DE), Fudan University (CN), University Hospital Bonn (DE), Hôpital Beaujon (FR), University Hospital Dubrava (HR), University Hospital of Bern (CH), Odense University Hospital (DK), Victor Babeș University of Medicine and Pharmacy Timișoara (RO), Hôpital Cochin (FR), European Foundation for the Study of Chronic Liver Failure (ES), Antwerp University Hospital (BE), University Hospital Münster (DE), Universitätsklinikum Knappschaftskrankenhaus Bochum (DE), Hôpital Edouard Herriot (FR), Zhongshan Hospital (CN), Institute of Clinical and Experimental Medicine (CZ), University Hospital Frankfurt (DE), Université d'Angers (FR), Medical University of Vienna (AT), Ruhr University Bochum (DE), KU Leuven (BE)
Good health and well-being
Openalex Percentile: Top 5%
Liver Disease Diagnosis and Treatment
4.25
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.